公开(公告)号：EP2331141A2

公开(公告)日：2011-06-15

申请号：EP09819622.3

申请日：2009-08-25

申请人： Excaliard Pharmaceuticals, Inc. ,  Isis Pharmaceuticals, Inc.

发明人： DEAN, Nicholas, M. ,  FOULKES, J. Gordon ,  O`DONNELL, Niall ,  BENNETT, C. Frank ,  FREIER, Susan M.

IPC分类号： A61K48/00

CPC分类号： C12N15/1136 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3521

摘要： This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

公开(公告)号：EP2331141B1

公开(公告)日：2016-01-06

申请号：EP09819622.3

申请日：2009-08-25

申请人： Excaliard Pharmaceuticals, Inc. ,  Isis Pharmaceuticals, Inc.

发明人： DEAN, Nicholas, M. ,  FOULKES, J. Gordon ,  O`DONNELL, Niall ,  BENNETT, C. Frank ,  FREIER, Susan M.

IPC分类号： C12N15/113 ,  A61K31/7088 ,  A61K48/00

CPC分类号： C12N15/1136 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3521

摘要： This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

公开(公告)号：EP3081648A1

公开(公告)日：2016-10-19

申请号：EP16150258.8

申请日：2009-08-25

申请人： Excaliard Pharmaceuticals, Inc. ,  Ionis Pharmaceuticals, Inc.

发明人： DEAN, Nicholas M. ,  FOULKES, J. Gordon ,  O'DONNELL, Niall ,  BENNETT, C. Frank ,  FREIER, Susan M.

IPC分类号： C12N15/113 ,  A61K31/7088 ,  A61K48/00

CPC分类号： C12N15/1136 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3521

摘要： This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

摘要翻译： 本发明提供了包含修饰的能够结缔组织因子和组合物治疗含病症Hyperprolific和纤维化疾病，以及瘢痕形成减少使用搜索化合物从伤口愈合所得的相同以及方法的抑制表达的寡核苷酸的化合物。

公开(公告)号：EP2906697A1

公开(公告)日：2015-08-19

申请号：EP13847099.2

申请日：2013-10-15

申请人： Isis Pharmaceuticals, Inc. ,  The Johns Hopkins University

发明人： BENNETT, C. Frank ,  FREIER, Susan M. ,  ROTHSTEIN, Jeffrey D. ,  DONNELLY, Christopher ,  SATTLER, Rita, G.

IPC分类号： C12N15/11 ,  C12N5/00 ,  C12N5/071 ,  C12Q1/68

CPC分类号： C12N15/113 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12N2310/3521

摘要： Disclosed herein are methods for monitoring expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such C9ORF72 specific inhibitors include antisense compounds.

公开(公告)号：EP1660682A2

公开(公告)日：2006-05-31

申请号：EP04781089.0

申请日：2004-08-12

申请人： ISIS PHARMACEUTICALS, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

发明人： MONIA, Brett P. ,  DOBIE, Kenneth W. ,  FREIER, Susan M. ,  POPOFF, Ian ,  WONG, Wai Shiu Fred ,  KARRAS, James G.

IPC分类号： C12Q1/68 ,  A01N43/04 ,  C07H21/04 ,  A61K31/07

CPC分类号： C12N15/1137 ,  A61K31/7052 ,  A61K38/00 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Y207/11024 ,  Y02P20/582 ,  C12N2310/3525

摘要： Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.

公开(公告)号：EP2758533A1

公开(公告)日：2014-07-30

申请号：EP12834215.1

申请日：2012-09-20

申请人： Isis Pharmaceuticals, Inc.

发明人： FREIER, Susan M. ,  BHANOT, Sanjay

IPC分类号： C12N15/113 ,  A61P3/08 ,  A61P3/10 ,  A61P7/12

CPC分类号： C12N15/1138 ,  A61K31/711 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/3525

摘要： Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.

公开(公告)号：EP2102340A2

公开(公告)日：2009-09-23

申请号：EP07862213.1

申请日：2007-11-27

申请人： Isis Pharmaceuticals, Inc.

发明人： FREIER, Susan M. ,  CROOKE, Rosanne M. ,  GRAHAM, Mark J. ,  TARBET, Kristina Lemonidis ,  BHANOT, Sanjay ,  TRIBBLE, Diane ,  WATTS, Andrew T.

IPC分类号： C12N15/11

CPC分类号： C12N15/1137 ,  A01K2227/105 ,  A01K2267/0375 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

公开(公告)号：EP0670897A1

公开(公告)日：1995-09-13

申请号：EP93923190.0

申请日：1993-10-01

申请人： ISIS PHARMACEUTICALS, INC.

发明人： MONIA, Brett P. ,  FREIER, Susan M. ,  ECKER, David J.

IPC分类号： C07K14 ,  C12N9 ,  C12N15 ,  C12Q1 ,  A61K38

CPC分类号： C07K14/82 ,  A61K38/00 ,  C12N2310/322 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2310/3533 ,  C12Q2525/125

摘要： Compositions and methods are provided for the modulation of expression of the human ras gene in both the normal and activated forms. Oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from the human ras gene, having nucleotide units sufficient in identity and number to effect such specific hybridization. Oligonucleotides specifically hybridizable with human H-ras and human Ki-ras are provided. Such oligonucleotides can be used for diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of the activated ras gene. Methods for diagnosis, detection and treatment of conditions arising from the activation of the H-ras or Ki-ras gene are also disclosed.

公开(公告)号：EP1660682B1

公开(公告)日：2011-10-05

申请号：EP04781089.0

申请日：2004-08-12

申请人： Isis Pharmaceuticals, Inc. ,  NATIONAL UNIVERSITY OF SINGAPORE

发明人： MONIA, Brett P. ,  DOBIE, Kenneth W. ,  FREIER, Susan M. ,  POPOFF, Ian ,  WONG, Wai Shiu Fred ,  KARRAS, James G.

IPC分类号： C12Q1/68 ,  A01N43/04 ,  C07H21/04 ,  A61K31/07

CPC分类号： C12N15/1137 ,  A61K31/7052 ,  A61K38/00 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Y207/11024 ,  Y02P20/582 ,  C12N2310/3525

摘要： Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.

公开(公告)号：EP2771463A1

公开(公告)日：2014-09-03

申请号：EP12843053.5

申请日：2012-10-25

申请人： Isis Pharmaceuticals, Inc.

发明人： FREIER, Susan M. ,  BHANOT, Sanjay

IPC分类号： C12N15/11 ,  C07H21/04 ,  C12N5/00

CPC分类号： C12N15/1138 ,  A61K31/7088 ,  A61K31/7115 ,  A61K31/712 ,  A61K31/7125 ,  A61K45/06 ,  C07H21/04 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525 ,  C12N2310/3521

摘要： Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.